@article{8bc5e4bb1c3b4a6394aa91912c4d7e62,
title = "Potential for overuse of corticosteroids and vasopressin in septic shock",
author = "Hsu, {Joe L.} and Vincent Liu and Patterson, {Andrew J.} and Martin, {Greg S.} and Nicolls, {Mark R.} and Russell, {James A.}",
note = "Funding Information: JAR reports holding stock in Sirius Genomics Inc., which has submitted patents owned by the University of British Columbia (UBC) and licensed to Sirius Genomics, that is related to the genetics of sepsis and its treatment. The UBC has also submitted a patent related to the use of vasopressin in septic shock. JAR reports being an inventor on these patents. JAR reports receiving consulting fees from Ferring Pharmaceuticals (which manufactures vasopressin and is developing a selective V1a agonist), from Astra Zeneca (which is developing an anti-TNFα), from BioCritica (which used to sell activated protein C in the USA), from MeImmune, and from Sirius Genomics Inc. JAR reports having received grant support from Sirius Genomics, Ferring Pharmaceuticals, Astra Zeneca and Eli Lilly that is provided to and administered by the UBC. JAR has received speaking honoraria from Pfizer and Eli Lilly.",
year = "2012",
month = sep,
day = "6",
doi = "10.1186/cc11460",
language = "English (US)",
volume = "16",
journal = "Critical Care",
issn = "1364-8535",
publisher = "BioMed Central",
number = "5",
}